Radar · Biopharma Outsourcing in Seoul
Best Biopharma Outsourcing Companies in Seoul, South Korea
The 31 best Biopharma Outsourcing companies in Seoul, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals.
By Rohit KhannaTrends & Stories
31companies tracked
$0disclosed funding
0unicorns
—have raised
FLIAR INTELLIGENCE · BIOPHARMA OUTSOURCING × SEOUL
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
100companies analysed
68%cloud-native stacks
2025funding peak (by rounds)
2008median founding year
50median Fliar Index™
Ranked: Best Biopharma Outsourcing companies in Seoul
| # | Company | Disclosed funding | Employees | Founder | Founded | Stage | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Daewoong Company that develops, manufactures, and commercializes prescription drugs | — | 1,644 | Seng-Ho Jeon CEO | 1945 | Unfunded | WordPressMySQLPHP+19 | 407 patents Botulinum toxin production, purification, formulation, and muscle‑targeting fusion protein therapeutics | — |
| 2 | Jeil Pharmaceutical Manufactures APIs and intermediates | — | 1,003 | Seung Soo Han Chairman & CEO | 1959 | Public | Windows ServerMicrosoft ASP.NETIIS+2 | 191 patents Patents concentrated in chemistry & materials | — |
| 3 | DAI HAN PHARM Manufacturer of generic infusion products | — | 691 | Yoon Woo Lee Chairman & CEO | 1945 | Public | PHPApache HTTP ServerjQuery UI+2 | — | — |
| 4 | Genuone Sciences Provider of drug formulation and supply chain services to biopharma sector | — | 677 | Clara Kim CEO | 2020 | Funding Raised | — | 21 patents Fixed-dose combination drug formulations for diabetes, cardiovascular, and allergy therapies | — |
| 5 | CKD bio Company engaged in manufacturing APIs and intermediates, and specializing in fermentation based production | — | 558 | — | 1941 | Public | — | 115 patents Probiotic strains for treating fatty liver, cognitive decline, and related metabolic disorders | — |
| 6 | Reyon Pharmaceutical Manufacturer of finished formulations and APIs | — | 492 | Jung Soon-Ock Chairman & CEO | 1955 | Public | — | 41 patents Electroporation-mediated gene delivery formulations and injection devices for therapeutic proteins | — |
| 7 | C&R Research Full-service Korean CRO specializing in oncology trials, early stage development and pharmacovigilance | — | 400 | Moon Tae Yoon CEO & President | 1997 | Public | — | 39 patents Robotic systems for autonomous navigation, rehabilitation assistance, and human‑power augmentation. | — |
| 8 | Hyundai Pharm Manufacturer of pharmaceuticals and consumer health products | — | 378 | — | 1965 | Public | DreamWeaverJavaFacebook Login+8 | 226 patents Patents concentrated in chemistry & materials | — |
Funding & investor landscape
$0total disclosed funding
0companies funded
0disclosed rounds
0rounds last 90 days
Most active investors
Prism market signals · South Korea · country-scoped Prism corpus, 601,318 docs
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN SEOUL · Health & Bio
How research on Biotechnology in Seoul is moving
A read on the academic research around Biotechnology in Seoul — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 68 papers.
68 papers · stance +0.47 · 27% breakthrough · 14% concern
top institutions
- Seoul National University53
- Seoul National University Hospital5
- Seoul National University of Science and Technology4
- University of Seoul2
- Seoul Women\'s University2
leading researchers
Hokyoung Son · Kim, V. Narry · Rui Liu · Seo, Jenny · Soobin Shin · A.A. АDAMBAYEVA
prism intelligence · tone & topics
87% positive · 9% critical tone
HealthMedical ResearchPharmaceuticalsAgricultureBiologyGenetics
▲
Breakthroughs16 · 24%
▼ 50%→22% share
▼0.4× share momentum0 median citations81% since 2021mostly empirical
Breakthroughs are cooling (50%→22% of field), led by In vivo.
rising sub-themes (early→recent)
- In vivo2
- Antibody2
- Strain (injury)2
- Histone2
- Induced pluripotent stem cell1
Landmark Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins · 1,853 cites
◆
Advancements35 · 51%
50%→50% share
▲1.0× share momentum0 median citations83% since 2021mostly empirical
Advancements are cooling (50%→50% of field), led by Mesenchymal stem cell.
rising sub-themes (early→recent)
- Mesenchymal stem cell1→3
- DNA damage1→3
Landmark Safety of Intravenous Infusion of Human Adipose Tissue-Derived Mesenchymal Stem Cells in Animals and Humans · 590 cites
▼
Concerns8 · 12%
▲ 0%→12% share
0 median citations88% since 2021mostly reviews
Concerns are rising (0%→12% of field), led by Polymerase chain reaction.
rising sub-themes (early→recent)
- Polymerase chain reaction1
- Real-time polymerase chain reaction1
- Polymerase1
- Chain (unit)1
- Genotoxicity1
Landmark Nano‐Sized CT Contrast Agents · 635 cites
Common questions
How many Biopharma Outsourcing companies are there in Seoul, South Korea?
Radar tracks 31 indexable Biopharma Outsourcing companies headquartered in Seoul, South Korea that meet our profile-completeness bar.
What is the total funding raised by Biopharma Outsourcing companies in Seoul, South Korea?
The Biopharma Outsourcing companies in Seoul, South Korea on this list have raised a combined $0 in disclosed equity funding across 0 funded companies.
Which is the highest-funded Biopharma Outsourcing company in Seoul, South Korea?
Funding figures are not yet disclosed for Biopharma Outsourcing companies in Seoul, South Korea.
How many Biopharma Outsourcing companies in Seoul, South Korea are funded?
0 of the 31 Biopharma Outsourcing companies in Seoul, South Korea on this list have disclosed at least one equity funding round.
How many Biopharma Outsourcing unicorns are there in Seoul, South Korea?
None of the Biopharma Outsourcing companies in Seoul, South Korea on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Seoul, South Korea Biopharma Outsourcing companies?
The most active investors in Seoul, South Korea Biopharma Outsourcing companies on this list include Company K Partners, Korea Investment Holdings, Alpen Route, GNTech Venture Capital, Hyundai Venture Investment.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.